Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 6;23(3):1844.
doi: 10.3390/ijms23031844.

Therapeutic Interventions to Mitigate Mitochondrial Dysfunction and Oxidative Stress-Induced Damage in Patients with Bipolar Disorder

Affiliations
Review

Therapeutic Interventions to Mitigate Mitochondrial Dysfunction and Oxidative Stress-Induced Damage in Patients with Bipolar Disorder

Sahithi Madireddy et al. Int J Mol Sci. .

Abstract

Bipolar disorder (BD) is characterized by mood changes, including recurrent manic, hypomanic, and depressive episodes, which may involve mixed symptoms. Despite the progress in neurobiological research, the pathophysiology of BD has not been extensively described to date. Progress in the understanding of the neurobiology driving BD could help facilitate the discovery of therapeutic targets and biomarkers for its early detection. Oxidative stress (OS), which damages biomolecules and causes mitochondrial and dopamine system dysfunctions, is a persistent finding in patients with BD. Inflammation and immune dysfunction might also play a role in BD pathophysiology. Specific nutrient supplements (nutraceuticals) may target neurobiological pathways suggested to be perturbed in BD, such as inflammation, mitochondrial dysfunction, and OS. Consequently, nutraceuticals may be used in the adjunctive treatment of BD. This paper summarizes the possible roles of OS, mitochondrial dysfunction, and immune system dysregulation in the onset of BD. It then discusses OS-mitigating strategies that may serve as therapeutic interventions for BD. It also analyzes the relationship between diet and BD as well as the use of nutritional interventions in the treatment of BD. In addition, it addresses the use of lithium therapy; novel antipsychotic agents, including clozapine, olanzapine, risperidone, cariprazine, and quetiapine; and anti-inflammatory agents to treat BD. Furthermore, it reviews the efficacy of the most used therapies for BD, such as cognitive-behavioral therapy, bright light therapy, imagery-focused cognitive therapy, and electroconvulsive therapy. A better understanding of the roles of OS, mitochondrial dysfunction, and inflammation in the pathogenesis of bipolar disorder, along with a stronger elucidation of the therapeutic functions of antioxidants, antipsychotics, anti-inflammatory agents, lithium therapy, and light therapies, may lead to improved strategies for the treatment and prevention of bipolar disorder.

Keywords: anti-inflammatory agents; antipsychotics; bipolar disorder; immune system dysregulation; light therapy; lithium therapy; mitochondrial dysfunctions; nutrients; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The potential interactions between BD, OS, mitochondrial dysfunction, immune dysfunction, antioxidants, antidepressant agents, anti-inflammatory agents, antipsychotic agents, and light therapies.

Similar articles

Cited by

References

    1. Husain S.F., Tang T.-B., Tam W.W., Tran B.X., Ho C.S., Ho R.C. Cortical haemodynamic response during the verbal fluency task in patients with bipolar disorder and borderline personality disorder: A preliminary functional near—Infrared spectroscopy study. BMC Psychiatry. 2021;21:201. doi: 10.1186/s12888-021-03195-1. - DOI - PMC - PubMed
    1. Muller J.K., Leweke F.M. Bipolar disorder: Clinical overview. Med. Mon. Pharm. 2016;39:363–369. - PubMed
    1. McIntyre R., Berk M., Brietzke E., Goldstein B.I., López-Jaramillo C., Kessing L.V., Malhi G.S., Nierenberg A.A., Rosenblat J.D., Majeed A., et al. Bipolar disorders. Lancet. 2020;396:1841–1856. doi: 10.1016/S0140-6736(20)31544-0. - DOI - PubMed
    1. Moreira F.P., Cardoso T.C., Mondin T.C., Wiener C.D., de Mattos Souza L.D., Oses J.P., Jansen K., da Silva R.A. Serum level of nerve growth factor is a potential biomarker of conversion to bipolar disorder in women with major depressive disorder. Psychiatry Clin. Neurosci. 2019;73:590–593. doi: 10.1111/pcn.12896. - DOI - PubMed
    1. Milev R. The role of electroconvulsive therapy in the treatment of bipolar disorder. In: Carvalho A.F., Vieta E., editors. The Treatment of Bipolar Disorder: Integrative Clinical Strategies and Future Directions. Oxford University Press; Oxford, UK: 2017. pp. 408–422.

MeSH terms